louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05245890: Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals
Official title: Assocaiton Between Uric Acid Trajecteries and Remission of Non-alcoholic Fatty Liver Disease (NAFLD) in NAFLD Individuals
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non-Alcoholic Fatty Liver Disease
Hyperuricemia
Lead sponsor: Ningbo No. 1 Hospital
Sponsor class: OTHER
Collaborators: name: The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
First posted: 2022-02-18
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People who undergo annual physical examinations in The First Affiliated Hospital, College of Medicine, Zhejiang University are enrolled in this study. People are divided into two groups according to hepatic ultrasonic examination at baseline: (1) individuals with NAFLD; (2) individuals without NAFLD.

Brief summary: Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence, and disease severity of non-alcoholic fatty liver disease (NAFLD).

Capitalizing on a cohort study in China, the investigators are aimed to assess the associations of SUA trajecteries with remission of NAFLD in NAFLD individuals and examined whether the association differs across subpopulations.

Detailed description: A cohort study was conducted to evaluate the relationship between the SUA trajecteries and remission of NAFLD. The study enrolled employees who were attending their annual health examination. Furrhermore, the investigators are aimed to explore whether the association differs across subpopulations.

Eligibility criteria: Inclusion Criteria:

1. age \>=18 years;
2. agree to be enrolled in this study.

Exclusion Criteria:

1. those taking antihypertensive or antidiabetic agents, lipid-lowing agents, or hypouricemic agents;
2. those with alcohol consumption greater than 140 g/week for men and 70 g/week for women;
3. those with a history of other known causes of chronic liver disease such as viral hepatitis or autoimmune hepatitis, and those using hepatotoxic medications.

Primary outcomes:
measure: the severity fatty liver evaluated by hepatic ultrasonic examination
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01655290: Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI
Official title: Single Dose Gadobutrol in Comparison to Single Dose Gadobenate Dimeglumine for Magnetic Resonance Imaging of Chronic Myocardial Infarction at 3 Tesla
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Subacute/Chronic Myocardial Infarction
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2012-08-01
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This study aims at evaluating the diagnostic efficacy of Gadobutrol versus Gadobenate dimeglumine at similar dose of 0.1mmol/kg for assessment of myocardial infarction by delayed enhancement cardiac Magnetic Resonance Imaging


Eligibility criteria: Inclusion Criteria:

* Diagnosis of myocardial infarction
* Age ≥ 18 years and ≤ 80 years
* Informed consent
* Male patients as well as female patients using contraceptives

Exclusion Criteria:

* Patients with a heart pacemaker, with magnetic material or other magnetic implants.
* Renal failure (GFR \<30ml/min)
* Patients with known allergy to a Gadolinium-containing contrast agent
* Drugs or alcohol addiction, dementia

Primary outcomes:
measure: Efficacy (contrast-to-noise ratio)
Secondary outcomes:
Other outcomes:
Locations:
city: Munic
country: Germany
facility: Institut für Radiologie - Klinikum Rechts der Isar
state: Bavaria
Study officials:
References:
Clinical trial NCT06001190: The Influence of Oral Probiotic on the Vaginal Flora and Microenvironment Alteration in the Vaginosis Infection Women
Official title: The Influence of Oral Probiotic on the Vaginal Flora and Microenvironment Alteration in the Vaginosis Infection Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Probiotic, Human Papillomavirus Infection, Pap Smear, Microbiome
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 76
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A single-blind, randomized, and probiotic-treatment including adult women with vaginitis and/or HPV positive. After oral probiotics, all participants will be followd-up cervical swabs and vaginal microbiome alteration till the end of the study.


Eligibility criteria: Inclusion Criteria:

* diagnosed as vaginal viginitis
* willing to sign permit
* willing to regular follow up

Exclusion Criteria:

* Pregnant
* Virgin
* Severe cervix pathology CINII or CIN III
* Confirmed cervical cancer
* under long term antibiotics due to other physical condition

Primary outcomes:
measure: improvement alteration of vaginal microbiome
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT01122290: Inducing Children's Emotional Eating
Official title: Inducing Preschool Children's Emotional Eating: Relationships With Parental Feeding Practices.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Emotional Eating Behaviour
Keywords: Emotional eating
Eating in the absence of hunger
emotion induction
Lead sponsor: University of Birmingham
Sponsor class: OTHER
Collaborators: name: Loughborough University
First posted: 2010-05-13
Enrollment: 64
Sex: ALL
Minimum age (years): 3
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy 3-5 year old children in the UK (within approx. radius of 10 miles of Loughborough University).

Brief summary: Background: Children's emotional eating is related to greater BMI and less healthy diet but little is known about the early development of this behavior.

Objective: This study aimed to examine the relationships between preschool children's emotional eating and parental feeding practices using experimental manipulation of child mood and food intake in a laboratory setting.

Design: 25 3-5 year old children and their mothers sat together and ate a standard meal to satiety. Mothers completed questionnaires about their feeding practices. Children were assigned to a control or negative mood condition. Children's consumption of snack foods in the absence of hunger was measured.


Eligibility criteria: Inclusion Criteria:

* Child age between 3 years and 5 years
* No disease/disorder affecting eating
* No learning disability

Exclusion Criteria:

* Any child brought in by a (non-primary care-giving) grandparent
* Child BMI at extreme of sample
* Incongruous mood shift to condition
* Child of non-english speaking/reading parent

Primary outcomes:
measure: eating in the absence of hunger
timeFrame: @ 60 minutes into study, at ~4 years of age
Secondary outcomes:
Other outcomes:
Locations:
city: Loughborough
country: United Kingdom
facility: School of Sport, Exercise and Health Sciences, Loughborough University
state: Leicestershire
Study officials:
References:
citation: Farrow CV, Haycraft E, Blissett JM. Teaching our children when to eat: how parental feeding practices inform the development of emotional eating--a longitudinal experimental design. Am J Clin Nutr. 2015 May;101(5):908-13. doi: 10.3945/ajcn.114.103713. Epub 2015 Mar 18.
citation: Blissett J, Haycraft E, Farrow C. Inducing preschool children's emotional eating: relations with parental feeding practices. Am J Clin Nutr. 2010 Aug;92(2):359-65. doi: 10.3945/ajcn.2010.29375. Epub 2010 Jun 9.
Clinical trial NCT02018003: The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Cervical Cancer Research
Official title: The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Stage Cervical Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Uterine Cervical Neoplasms
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2013-12-23
Enrollment: 180
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The women with early stage cervical cancer, who underwent operation in Peking University School of Oncology.

Brief summary: The purpose of this study is to assess the women's quality of life, who accepted chemotherapy,radiotherapy, concurrent radiochemotherapy or who didn't accept therapy, after operation.

Detailed description: The study projects to follow up 180-200 early stage cervical cancer patients after operation and assess the women's quality of life by the scales: ECOG, Functional Assessment of Cancer Therapy, EuroQol-5 Dimensions, and Kupperman index.

Eligibility criteria: Inclusion Criteria:

* ≮ 18 years, cervical cancer verified by pathology，

  * IIA stage, accepted the operation ( Piver III and pelvic lymph node dissection) as initial therapy， obtained the patient's agreement

Exclusion Criteria:

* the patient had accepted chemotherapy or radiotherapy before operation

Primary outcomes:
measure: Quality of life for the women with early stage cervical cancer who underwent operation
timeFrame: up to 12 months after operation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Peking University
name: Gao Yunong
role: STUDY_DIRECTOR
References:
Clinical trial NCT00116103: A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
Official title: A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asthma
Keywords: Treatment Effectiveness
Treatment Efficacy
Investigational, Therapies
Asthma
Antiasthmatics
Antiasthmatic agents
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Astellas Pharma US, Inc.
First posted: 2005-06-28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.

Detailed description: The purpose of this randomized, double-blind, placebo-controlled, parallel-group, multi-center designed trial is to determine the safety and efficacy of tacrolimus inhalation aerosol in subjects with persistent asthma.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of persistent asthma for at least 6 months
* Require use of beta-agonists at least four times per week

Exclusion Criteria:

* Diagnosis of chronic obstructive pulmonary disease (COPD)

Primary outcomes:
measure: The primary outcome is the change in FEV1 from baseline to end-treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
state: Arizona
city: Encinitas
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Jose
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: Daytona Beach
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Boise
country: United States
state: Idaho
city: River Forest
country: United States
state: Illinois
city: South Bend
country: United States
state: Indiana
city: St Louis
country: United States
state: Missouri
city: Missoula
country: United States
state: Montana
city: Omaha
country: United States
state: Nebraska
city: Cincinnati
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Providence
country: United States
state: Rhode Island
city: Spartanburg
country: United States
state: South Carolina
city: San Antonio
country: United States
state: Texas
city: Madison
country: United States
state: Wisconsin
city: Milwaukee
country: United States
state: Wisconsin
Study officials:
affiliation: Astellas Pharma US, Inc.
name: Astellas Medical Monitor, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00673803: Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification
Official title: Influence of Two Sharp-edged Hydrophobic Acrylic Micro-incision-IOLs on Posterior Capsule Opacification. A Randomized, Double-masked Study With Intraindividual Comparison.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Keywords: posterior capsule opacification
micro incision
sharp optic edge
Lead sponsor: Hospital Hietzing
Sponsor class: OTHER
First posted: 2008-05-07
Enrollment: 40
Sex: ALL
Minimum age (years): 55
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Studies showed that a sharp posterior optic edge of an intraocular lens (IOL) inhibits migration of lens epithelial cells in between posterior capsule and optic of the IOL and therefore reduces the rate of posterior capsule opacification (PCO). In present time most IOLs implanted have a sharp posterior optic edge. Due to differences in IOL production different IOLs have different rates of PCO.

Progression in cataract surgery technique allow phacoemulsification through micro-incisions. Therefore there is need for IOLs that can be implanted through incisions of about 2.5 mm.

This study investigates the effect of two different hydrophobic acrylic IOLs with a sharp posterior optic edge on the rate of PCO after implantation through a micro-incision. The results will be compared intraindividually.

Detailed description: prospective, randomized, bilateral study with intraindividual comparison, implantation of a Polylens Y10 IOL in one eye and implantation of a Polylens Y30 in the contralateral eye.

PCO rate will be detected at 1 year and 2 years.

Eligibility criteria: Inclusion Criteria:

* bilateral age-related cataract
* age 55 to 80 years
* expected postoperative visual acuity of at least 0.5

Exclusion Criteria:

* amblyopia
* corneal scars
* diabetes
* pseudoexfoliation-syndrome
* earlier ocular surgeries or laser treatments
* intraocular tumors

Primary outcomes:
measure: PCO rate
timeFrame: 2 years after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Ophthalmology, Hietzing Hospital
Study officials:
affiliation: Dept of Ophthalmology, Hietzing Hospital, Vienna, Austria
name: Nadja Karnik, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04506203: The Accuracy of Pediatric Air Test as a Non-invasive Atelectasis Diagnostic Tool
Official title: The Accuracy of Pediatric Air Test as a Non-invasive Atelectasis Diagnostic Tool: a Multi-centre Prospective Double-blind Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Collapse
Lung Diseases
Atelectasis
Atelectasis Without Respiratory Distress Syndrome
Atelectases, Resorption
Air Test
Pediatric Disorder
Keywords: air test
atelectasis
pediatric
non-invasive
lung collapse
Lead sponsor: Hospital Universitario La Paz
Sponsor class: OTHER
Collaborators: name: Hospital Universitario La Princesa
name: Hospital Privado de Comunidad
First posted: 2020-08-10
Enrollment: 108
Sex: ALL
Minimum age (years): 5
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: HYPOTHESIS:

During anesthetic pre-oxygenation with high FiO2, pulmonary atelectasis occur, especially in patients \< 6 years old, where FRC and pulmonary closing volume may overlap. New borns and children \<1 year old are especially vulnerable.

OBJECTIVES:

1. Validate "air test" as a individualized and non-invasive diagnostic method of clinically significant atelectasis in pediatrics.
2. Determine what other factors contribute to atelectasis development in pediatrics

METHODS:

30 pediatric patients will be studied with ages ranged between 45 postconceptional weeks and16 years old.

Baseline SpO2 and lung ultrasound will be performed for each patient upon arrival at the operating theatre before preoxygenation with FiO2 of 1.0 SpO2 will be measured 15 min after intubation during a 5 min long "air test" trial (FiO2 0.25). lung collapse will be verified by lung ultrasound at the end of the 15 min trial. Lung collapse will be eventually granted upon lung US verification by a blind researcher.


Eligibility criteria: Inclusion Criteria:

* General anesthesia
* Perioperative risk classification (ASA) I, II, III
* Newborns (postconceptional age\> 45 weeks) to 16 years
* Need for oral / nasotracheal intubation

Exclusion Criteria:

* ASA \> III
* Basal SpO2 \< 97% on air in supine position
* Preoperative need for oxygen therapy and / or high-flow nasal cannulas
* Expected Difficult airway
* Presence of craniofacial disorders that may compromise ventilation
* Hemodynamic instability and / or need for inotropics
* History of untreated heart disease
* Presence or history of pneumothorax
* Presence of untreated congenital pulmonary disorders
* Refusal to participate in the study

Primary outcomes:
measure: Atelectasis incidence
timeFrame: 5 minutes
measure: Accuracy of Pediatric Air test trial
timeFrame: 5 minutes
Secondary outcomes:
measure: Atelectasis risk factors assessment
timeFrame: 5 minutes
measure: Atelectasis severity
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Córdoba
country: Argentina
facility: Hospital Privado de Comunidad
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Madrid
country: Spain
facility: Hospital Universitario La Princesa
Study officials:
References:
Clinical trial NCT06851403: The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
Official title: The Effectiveness and Safety of Dupilumab in Children with Severe Asthma in China: a Real-world Study
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Asthma in Children
Keywords: type 2 inflammation
asthma
dupilumab
Lead sponsor: Guangzhou Institute of Respiratory Disease
Sponsor class: OTHER
First posted: 2025-02-28
Enrollment: 213
Sex: ALL
Minimum age (years): 4
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl.

Brief summary: Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.


Eligibility criteria: Inclusion Criteria:

Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period.

Exclusion Criteria:

Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.

Primary outcomes:
measure: FEV1
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
measure: FVC
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
measure: FEV1/FVC
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
measure: PEF
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
Secondary outcomes:
measure: FeNO
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
measure: blood EOS
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
measure: percentage of sputum eosinophils
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
measure: TIgE
timeFrame: From enrollment to the end of treatment through study completion, an average of 1 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangzhou institute of respiratory disease
state: Guangdong
Study officials:
References: